Abstract
Background: Type-2 Diabetes Mellitus (T-2 DM) patients, with hyperglycemia, have increased intracellular glycogen storage and Free Fatty Acid (FFA) accumulation in hepatocyte in response to insulin resistance leading to increase glycogen synthesis and FFA production which are toxic to hepatocytes, causing hepatocellular injury, fatty changes in liver and elevation of aminotransferases levels. Raised liver enzymes are marker of hepatocellular injury and can be used as an indirect evidence of insulin resistance in Type-2 DM.
Objective: To know the extent of liver structure and functions are modified in Type-2 DM patients, by estimating serum biochemical analysis of liver functions in relation to glycemic status and Ultrasound study of liver to detect fatty changes.
Material and Method: This was an observational cross sectional study on 100 T2DM patients and 100 age and sex matched controlled non-diabetic cases attending the Department of Medicine, VSSIMSAR. BURLA from October 2017 to November 2019. Biochemical tests were done for assessment of glycemic status were, FBS, PPBS, HbA1C and for liver functions, total, direct and indirect bilirubin, ALT, AST, ALP, Total protein and serum Albumin. Ultrasonography study of liver was done for detection of hepatic structure and pathology.
Result: Total bilirubin was elevated in 13% and Direct bilirubin elevated in 36%, AST, ALT, ALP was increased in 46%, 62%, and 46% cases respectively from normal cutoff values. Serum albumin value was decreased in 44%. On USG study 16 T-2DM patients (17.39%) had Fatty liver changes. Type-2 DM patients with fatty liver changes had raised liver enzymes, PPBG and HbA1C, suggesting high insulin resistance state in comparison to patients without fatty liver changes..
Conclusion: Mild raised liver enzymes and fatty liver changes may be used as an indirect biomarker of insulin resistance in type-2 DM.
Keywords: Type-2 Diabetes, Liver Functions, Insulin resistance, Fatty liver, ALT, AST, ALP, HbA1c.
References
- American Diabetic Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2008; 31:S62–7.
- Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes care 2004; 27(5):1047-53.
- Kenneth Cusi. Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Current Opinion in Endocrinology, Diabetes & Obesity 2009; 16:141-149.
- Agarwal J .Prevalence of elevated hepatic enzymes among North Indian patients withtype 2 diabetes mellitus. Santosh University J Health Sci 2015; 1:3-6.
- Kratz A Sluss PM, Januzzi JL Jr., Lewandrowski KB. Appendices: Laboratory values of clinical importance. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison's Principles of Internal Medicine. 16th ed. The United States of America: The McGraw-Hill Companies, Inc.; p. A1-7
- Nil H, Soe HHK, Htet A. Determinants of Abnormal Liver Function Tests in Diabetes Patients in Myanmar. International Journal of Diabetes Research. 2012; 1(3):36-41.
- Gonem S, Wall A, De P. Prevalence of abnormal liver function test in patients with diabetes mellitus. Endocrine Abstract.2007; 13:P157.
- Meybodi M A, Afkhami- Ardekani M, Rashidi M. Prevalence of Abnormal Serum Alanine Aminotransferase Levels in Type 2 Diabetic Patients in Iran. Pakistan Journal of Biological Sciences 2008; 11:2274-2277.
- Bora K, Borah M, Chutia H, Nath CK, Das, D, Ruram AA. Presence of concurrent derangements of liver function tests in type 2 diabetes and their relationship with glycemic status: A retrospective observational study from Meghalaya. J Lab Phys 2016; 8(1): 30-35.
- Balogun WO, Adeleye JO, Akinlade KS, Adedapo KS, KutiM . Frequent occurrence of high gamma-glutamyltransferase and alanine amino transferase among Nigerian patients with type 2 diabetes.
- Fatema K, Dparvin, Sislam et al, Deranged liver function test in Type-2 Diabetes: a retrospective study, jmedbiochem 2017;10(2).
- JudiL, Toukan A, Khader Y, Ajlouni K, Khatib MA. Prevalence of elevated hepatic transaminases among Jordanian patients with Type-2 diabetes mellitus. Ann Saudi Med 30:25-32.
- Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997; 26:143-146.
Corresponding Author
Dr Jyotiprakash Patel
Junior Resident, Department of Internal Medicine, VSSIMSAR, Burla, Sambalpur, Odisha, 768017
DOI: https://dx.doi.org/10.18535/jmscr/v8i1.99
